Quarterly ResultAug 6, 2026, 08:33 AM
Sonoma Pharma Q2 Revenue +59.5% to $6.41M; Net Loss $(0.33M)
AI Summary
Sonoma Pharmaceuticals reported a significant improvement in its second-quarter 2026 financial results, with revenues increasing by 59.5% to $6.41 million and net loss narrowing to $(0.33) million from $(1.24) million in the prior year. The company also successfully completed an equity offering, raising $3.48 million in net proceeds, which substantially boosted its cash position and working capital. Management believes current liquidity is sufficient for the next twelve months.
Key Highlights
- Revenue increased by 59.5% to $6.41 million for the three months ended June 30, 2026, from $4.02 million in 2025.
- Net loss significantly narrowed to $(0.33) million, an improvement from $(1.24) million in the same period last year.
- Diluted net loss per share improved to $(0.09) from $(0.76) year-over-year.
- Cash and cash equivalents rose to $5.34 million at June 30, 2026, from $2.40 million at March 31, 2026.
- Working capital increased to $10.82 million at June 30, 2026, from $7.27 million at March 31, 2026.
- Net cash used in operating activities decreased to $(0.65) million from $(2.02) million in the prior year.
- Completed an equity offering, raising $3.48 million in net proceeds by issuing 2,962,963 shares and warrants.
- Human Care revenue grew to $5.97 million from $3.56 million, while US revenue increased to $2.43 million from $1.01 million.
Price Impact
More from SNOA